Collaborate with usWhat’s new?
About us

Click Therapeutics is redefining
modern medicine with patient-centric
digital treatments.

We develop, validate, and commercialize software as prescription medical treatments for people with unmet medical needs. 

Digital Treatments.Tangible Outcomes.

Our Mission

Provide patients everywhere access to safe and effective prescription digital therapeutics.

In 2012, our founder and CEO David recognized the enormous impact of smartphones on behavior and cognition. 

Driven by the opportunity to leverage software to improve clinical outcomes and bridge gaps in treatment access, he began a journey to develop innovative mobile-application-based treatments. He created a term for this new modality of medicine, Digital Therapeutics™, and founded Click Therapeutics, which develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. 

Click Therapeutics is paving the way for a healthcare system where digital treatments, such as prescription digital therapeutics, can reduce suffering on a global scale. Operating at the intersection of biology and technology, Click combines neuroscience with the power of software, creating a new way to treat disease.

A few things to know about us

We are expanding the possibilities of medicine with Digital Therapeutics™ that combine clinical science with the power of software to create a new way to treat disease.  

Read about our approach

We have a leading AI-enabled prescription digital therapeutics platform.

In collaboration with Otsuka, we developed the first and only prescription app for the adjunctive treatment of MDD symptoms.

CT-132, Click's investigational PDT for preventive treatment of episodic migraine, met primary endpoint for the reduction of monthly migraine days in ReMMi-D pivotal trial.

We are supported by biotech/pharma investor base, including HIG, Accelmed, & Sanofi Ventures.

Our multidisciplinary team of innovators

Our diverse team of innovators—spanning clinicians, researchers, and technologists—works together to create cutting-edge software as medicine, united in the mission to transform patient care.

Meet our team
The Click Way
  1. 01Patients First

    Place patients and their loved ones at the center of what you do.

  2. 02Act with Integrity

    Be honest, transparent, and follow the Golden Rule.

  3. 03Expect Excellence

    Challenge mediocrity, foster quality.

  4. 04No Jerks

    Be collegial and considerate.

  5. 05Own It

    Do what you say and be accountable for results.

  6. 06Make Work Fun

    Make the environment as enjoyable as possible.

Awards

  • PV100 Logo

    David Benshoof Klein, our founder and CEO was named to the 2024 PharmaVoice 100 list, recognizing him as a top leader in the life-sciences industry within the Tech and AI category.

  • 1736265016427

    Click Therapeutics has been honored with the Builtin Best Places to Work award, recognizing companies who offer the best compensation packages, total rewards and culture programs among their peers, for the last 4 years.

  • Screenshot 2025 02 06 at 1 02 16 PM

    Click Therapeutics was recognized on the DHNY Hall of Fame 2025 list, which honors the pioneering companies that have laid the foundation for New York’s thriving digital health ecosystem.

  • Click Tx Deloitte Fast 500

    Click Therapeutics has received the 2024 Deloitte Technology Fast 500 Award, celebrating the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, for the last 2 years. 

Join us in developing the next generation of medicine. View current job openings

View current job openings

Discover our products

CT-156

CT-156

Indication

Schizophrenia

Collaborator

Boehringer Ingelheim

Phase

Phase 2: Dev/Pilot
CT-102

CT-102

Indication

Opioid Use Disorder (OUD)

Collaborator

Phase

Phase 2: Dev/Pilot
CT-133

CT-133

Indication

Multiple Sclerosis (MS)

Collaborator

Phase

Phase 1: Discovery
CT-171

CT-171

Indication

Atopic Dermatitis

Collaborator

Phase

Phase 1: Discovery
CT-181

CT-181

Indication

Obesity

Collaborator

Phase

Phase 1: Discovery
CT-191

CT-191

Indication

Oncology

Collaborator

Phase

Phase 1: Discovery
CT-141

CT-141

Clickadian™

Indication

Insomnia

Collaborator

Phase

Phase 1: Discovery
CT-111

CT-111

Clickheart™

Indication

Acute Coronary Syndrome

Collaborator

Phase

Phase 1: Discovery
CT-156

CT-156

Indication

Schizophrenia

Collaborator

Boehringer Ingelheim

Phase

Phase 2: Dev/Pilot
CT-102

CT-102

Indication

Opioid Use Disorder (OUD)

Collaborator

Phase

Phase 2: Dev/Pilot
CT-133

CT-133

Indication

Multiple Sclerosis (MS)

Collaborator

Phase

Phase 1: Discovery
CT-171

CT-171

Indication

Atopic Dermatitis

Collaborator

Phase

Phase 1: Discovery
CT-181

CT-181

Indication

Obesity

Collaborator

Phase

Phase 1: Discovery
CT-191

CT-191

Indication

Oncology

Collaborator

Phase

Phase 1: Discovery
CT-141

CT-141

Clickadian™

Indication

Insomnia

Collaborator

Phase

Phase 1: Discovery
CT-111

CT-111

Clickheart™

Indication

Acute Coronary Syndrome

Collaborator

Phase

Phase 1: Discovery